Cargando…
Organoids as a Systems Platform for SCLC Brain Metastasis
Small Cell Lung Cancer (SCLC) is a highly aggressive, neuroendocrine tumor. Traditional reductionist approaches have proven ineffective to ameliorate the uniformly dismal outcomes for SCLC – survival at 5 years remains less than 5%. A major obstacle to improving treatment is that SCLC tumor cells di...
Autores principales: | Quaranta, Vito, Linkous, Amanda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096159/ https://www.ncbi.nlm.nih.gov/pubmed/35574308 http://dx.doi.org/10.3389/fonc.2022.881989 |
Ejemplares similares
-
Low radiotherapy dose is suitable for brain metastases in SCLC compared with high dose
por: Xu, Liming, et al.
Publicado: (2023) -
Generating Patient-Derived Gliomas within Cerebral Organoids
por: Linkous, Amanda, et al.
Publicado: (2020) -
Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance: Understanding SCLC heterogeneity and plasticity in metastasis and chemoresistance
por: Jin, Yujuan, et al.
Publicado: (2023) -
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs
por: Belluomini, Lorenzo, et al.
Publicado: (2022) -
Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
por: Saltos, Andreas, et al.
Publicado: (2020)